Atezolizumab, approved by the FDA, is also effective for adjuvant treatment in patients with stage II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection and platinum-based chemotherapy, with PD-L1 SP263 expression detected in ≥ 1% of tumor cells [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.